Literature DB >> 9511824

Plasmid-mediated rifampicin resistance in Pseudomonas fluorescens.

S Chandrasekaran1, D Lalithakumari.   

Abstract

Rifampicin is an antibiotic mostly used to treat tuberculosis and leprosy, and, occasionally, other diseases. Resistance is due to alterations in membrane permeability or to mutation in the rpoB gene coding for mRNA polymerase. Both these mechanisms originate via chromosomal mutation. However, a rifampicin-resistant Pseudomonas fluorescens strain harboured a multiresistance plasmid which transferred rifampicin resistance when transformed into P. putida or Escherichia coli. Rifampicin readily diffused into the sensitive cells of the E. coli and P. putida recipients, but the transformants with the plasmid, pSCL were resistant to the drug and did not accumulate it. Potassium cyanide restored the diffusion of rifampicin into the resistant cells, indicating that an efflux pump was involved in the resistance mechanism. The resistance of the transformants and the wild strain was also abolished in sphaeroplasts generated by EDTA lysozyme treatment. Analysis of membrane proteins by SDS-PAGE revealed the presence of two new proteins in the plasmid-containing cells of E. coli, P. putida and P. fluorescens and not in the plasmid-free cells. These may be involved in the efflux of rifampicin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9511824     DOI: 10.1099/00222615-47-3-197

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

1.  Plasmid-mediated rifampin resistance encoded by an arr-2-like gene cassette in Klebsiella pneumoniae producing an ACC-1 class C beta-lactamase.

Authors:  G Arlet; D Nadjar; J L Herrmann; J L Donay; P H Lagrange; A Philippon
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

2.  Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.

Authors:  Andrei Kutlin; Stephan Kohlhoff; Patricia Roblin; Margaret R Hammerschlag; Paul Riska
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Characterization of In53, a class 1 plasmid- and composite transposon-located integron of Escherichia coli which carries an unusual array of gene cassettes.

Authors:  T Naas; Y Mikami; T Imai; L Poirel; P Nordmann
Journal:  J Bacteriol       Date:  2001-01       Impact factor: 3.490

4.  Integron-mediated rifampin resistance in Pseudomonas aeruginosa.

Authors:  C Tribuddharat; M Fennewald
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 5.  Rifamycin antibiotics and the mechanisms of their failure.

Authors:  Rebekah A Adams; Gabrielle Leon; Natalia M Miller; Saira P Reyes; Chantal H Thantrong; Alina M Thokkadam; Annabel S Lemma; Darshan M Sivaloganathan; Xuanqing Wan; Mark P Brynildsen
Journal:  J Antibiot (Tokyo)       Date:  2021-08-16       Impact factor: 2.649

Review 6.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

7.  Antibacterial and antivirulence effect of 6-N-hydroxylaminopurine in Listeria monocytogenes.

Authors:  Stefanie Sandra Krajewski; Isabelle Isoz; Jörgen Johansson
Journal:  Nucleic Acids Res       Date:  2017-02-28       Impact factor: 16.971

Review 8.  Pseudomonas fluorescens Complex and Its Intrinsic, Adaptive, and Acquired Antimicrobial Resistance Mechanisms in Pristine and Human-Impacted Sites.

Authors:  Myllena Pereira Silverio; Gabriela Bergiante Kraychete; Alexandre Soares Rosado; Raquel Regina Bonelli
Journal:  Antibiotics (Basel)       Date:  2022-07-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.